Taysha Gene Therapies
TSHA----
Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for t...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Taysha Gene Therapies Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$13.15125.62%
Forecast & RatingStrong buy
13analysts
- Strong buy76.92%
- Buy23.08%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 hour ago
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by Brokerages
- Simplywall · Jul 16 at 08:16 AM
Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?
- PUBT · Jul 10 at 05:55 PM
Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million
- Simplywall · Jul 10 at 08:17 AM
Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop
- Global Report · Jul 8 at 10:32 PM
Under the Radar: The Tech, Biotech, and Defense Shifts You Missed
- Tip Ranks · Jun 30 at 01:35 PM
Buy Rating Reaffirmed on Taysha’s Superior Trial Rigor and Safety Profile; $12 Price Target Maintained
